Evidence map›Paper›PMID 25148255›Full record

Trial reportPloS one2014

Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses.

Minami Ohara, Harumi Takahashi, Ming Ta Michael Lee, Ming-Shien Wen, Tsong-Hai Lee, Hui-Ping Chuang, Chen-Hui Luo, Aki Arima, Akiko Onozuka, Rui Nagai and 4 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02065388 (Pharmacogenetic Dosing of Warfarin), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02065388 phase3completednot on this map

Pharmacogenetic Dosing of Warfarin

TypeinterventionalSponsorAcademia Sinica, TaiwanRan2009 to 2013Enrolled300ConditionsStroke, Venous Thrombosis, Atrial Fibrillation, Atrial FlutterArmsStandard of care dosing for warfarin, Genotype-guided dosingTaiwan algorithm for warfarin, Genotype-guided dosing IWPC algorithm for warfarin
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. A Tutorial on Pharmacodynamic Scripting Facility in Simcyp.CPT: pharmacometrics & systems pharmacology · 2016
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Minami OharaDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
Harumi TakahashiDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
Ming Ta Michael LeeLaboratory for International Alliance on Genomic Research, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Ming-Shien WenDepartments of Medicine and Neurology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.
Tsong-Hai LeeDepartments of Medicine and Neurology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.
Hui-Ping ChuangInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Chen-Hui LuoDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
Aki ArimaDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
Akiko OnozukaDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
Rui NagaiDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
Mari ShiomiDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
Kiyoshi MiharaFaculty of Pharmacy, Center for Clinical Pharmacy, Musashino University, Tokyo, Japan.
Takashi MoritaSchool of Medicine, Juntendo University, Tokyo, Japan.
Yuan-Tsong ChenInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledTo clarify pharmacokinetic-pharmacodynamic (PK-PD) factors associated with the over-anticoagulation response in Asians during warfarin induction therapy, population PK-PD analyses were conducted in an attempt to predict the time-courses of the plasma S-warfarin concentration, Cp(S), and coagulation and anti-coagulation (INR) responses. In 99 Chinese patients we analyzed the relationships between dose and Cp(S) to estimate the clearance of S-warfarin, CL(S), and that between Cp(S) and the normal prothrombin concentration (NPT) as a coagulation marker for estimation of IC50. We also analyzed the non-linear relationship between NPT inhibition and the increase in INR to derive the non-linear index λ. Population analyses accurately predicted the time-courses of Cp(S), NPT and INR. Multivariate analysis showed that CYP2C9*3 mutation and body surface area were predictors of CL(S), that VKORC1 and CYP4F2 polymorphisms were predictors of IC50, and that baseline NPT was a predictor of λ. CL(S) and λ were significantly lower in patients with INR≥4 than in those with INR<4 (190 mL/h vs 265 mL/h, P<0.01 and 3.2 vs 3.7, P<0.01, respectively). Finally, logistic regression analysis revealed that CL(S), ALT and hypertension contributed significantly to INR≥4. All these results indicate that factors associated with the reduced metabolic activity of warfarin represented by CL(S), might be critical determinants of the over-anticoagulation response during warfarin initiation in Asians.

trial registrationClinicalTrials.gov NCT02065388.

Indexed as

AgedAnticoagulantsAsian PeopleCytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemCytochrome P450 Family 4Dose-Response Relationship, DrugFemaleHumansLogistic ModelsMaleMiddle AgedMutationPolymorphism, GeneticTreatment OutcomeVitamin K Epoxide ReductasesAnticoagulantsCYP2C9 protein, humanCYP4F2 protein, humanCytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemCytochrome P450 Family 4Vitamin K Epoxide ReductasesVKORC1 protein, humanWarfarin

Identifiers

PMID25148255
PMCPMC4141831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.